Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: Randomized, double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 61-65

  Aliyev, Nadir A ^a   Aliyev, Zafar N ^b  

^a Mental Clinic for Outpatients of Baku City   (Azerbaijan)

^b Psychiatric Department   (Azerbaijan)

Author keywords

depersonalization disorder; lamotrigine; treatment

Indexed keywords

LAMOTRIGINE; PLACEBO;

ADULT; AGED; ARTICLE; BLURRED VISION; CAMBRIDGE DEPERSONALIZATION SCALE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; MALE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SOMNOLENCE; TREATMENT RESPONSE; UNSTEADINESS; VOMITING;

ADULT; AMBULATORY CARE; COMORBIDITY; DEPERSONALIZATION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 78651307268     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820428e1     Document Type: Article

References (24)

1. Sierra M. Depersonalization disorder: pharmacological approaches. Expert Rev Neurother. 2008;8:19-26.
2. Shader RI. Manual of Psychiatric Therapeutics. 2nd ed. Boston, MA: Little, Brown and Company; 1994.
3. Nuller YL. DepersonalisationVsymptoms, meaning, therapy. Acta Psychiatr Scand. 1982;66:451-458.
4. Nuller YL, Morozova MG, Kushnir ON, et al. Effect of naloxone therapy on depersonalization: a pilot study. J Psychopharmacol. 2001;15:93-95.
5. Gelder M, Gath D, Mayou R. Oxford Textbook of Psychiatry. 2nd ed. Oxford, NY: Oxford University Press; 1989.
6. Medford N, Sierra M, Baker D, et al. Understanding and treating depersonalisation disorder. Adv Psychiatr Treat. 2005;11:92-100.
7. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270-276.
8. Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs. 2004;18:343-354.
9. Sierra M, Phillips ML, Ivin G, et al. A placebo-controlled crossover trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003;17:103-105.
10. Hollander E, Liebowitz MR, DeCaria C, et al. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990;10:200-203.
11. Fichtner CG, Horevitz RP, Braun BG. Fluoxetine in depersonalisation disorder [letter]. Am J Psychiatry. 1992;149:1750-1751.
12. Ratliff NB, Kerski D. Depersonalization treated with fluoxetine [letter]. Am J Psychiatry. 1995;152:1689-1690.
13. Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol Psychiatry. 1998;44:302-303.
14. Sierra M, Berrios GE. A case of depersonalization. Hist Psychiatry. 1996;7:451-461.
15. Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res. 2000;93:153-164.
16. Glantz AS. Primer of Biostatistics. Danilov IA, trans. Praktika [Russian translation]. Moscow, Russia: Patrica; 1999.
17. Sierra M, Phillips ML, Lambert MV, et al. Lamotrigine in the treatment of depersonalization disorder. J Clin Psychiatry. 2001;62:826-827.
18. Sachdev P. Citalopram-clonazepam combination for primary depersonalization disorder: a case report. Aust N Z J Psychiatry. 2002;36:424-425.
19. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999;60:598-603.
20. Walsh SL, Strain EC, Abreu ME, et al. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001;157:151-162.
21. Sierra M, Berrios GE. The phenomenological stability of depersonalization: comparing the old with the new. J Nerv Ment Dis. 2001;189:629-636.
22. Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology. 2005;181:415-436.
23. Stein MB, Uhde TW. Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biol Psychiatry. 1989;26:315-320.
24. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 1998;38:119-130.